Tumor microenvironment as a therapeutic target in cancer

By Yi Xiao, Dihua Yu. Pharmacology and Therapeutics, 2020

1,690 citations recorded by the source corpus.

Tumor microenvironment denotes the non-cancerous cells and components presented in the tumor, including molecules produced and released by them. The constant interactions between tumor cells and the tumor microenvironment play decisive roles in tumor initiation, progression, metastasis, and response to therapies. The tumor microenvironment as a therapeutic target in cancer has attracted great research and clinical interest. Here we summarize the current progress in targeting the tumor microenvironment in both drug development and clinical trials; highlight challenges in targeting the tumor microenvironment to achieve therapeutic efficacy; explore new technologies and approaches to better decipher the tumor microenvironment; and discuss strategies to intervene in the pro-tumor microenvironment and maximize therapeutic benefits.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/29255b5da6c5887566acdea277c7fe065bc5a70a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. C. Shi
2. Shijun Li
3. Zhiwen Fu
4. Yu Zhang
5. Sifei Han

Citations in the corpus

• Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research (2022, background): “The TME includes noncancerous cells, including components that are also present in the tumor, such as immune cells, CAFs, endothelial cells, mesenchymal stroma/stem cells (MSCs), extracellular matrix compounds, and soluble products such as chemokines, cytokines, growth factors, and extracellular ves”
• Antibody drug conjugate: the “biological missile” for targeted cancer therapy (2022, background): “Emerging evidence in the preclinical and clinical setting suggests that components of the neovascular system, subendothelial extracellular matrix and tumor matrix could be valuable target antigens for ADC drug development.(27) For example, matrix targeted ADC drugs has the potential to cause cancer ”